Biotech Values

[tinkershaw]

Yes, it looks like to me this puts a big dent in the PI argument. It also dramatically reduces the damages that MNTA could have potentially have claimed. And by doing so it also dramatically reduces Amphastar/Watson's risk if they decide to launch at risk, which at this point in time I believe they will given the reduced risk if the PI is not granted.

It also dramatically reduces the value of MNTA's enoxaparin IP, as keeping out a competitor now is worth in the $10s of millions per year and not hundreds of millions anymore with an AG.

All in all, a broadside hit, making this litigation less imperative, less valuable, less defining for MNTA. MNTA now has copaxone as its next big thing and enoxaparin should become baked in as a given at this point in time in regard to dramatically reduced revenues.

Talk about taking air out of the balloon. But there is no PI vs. an AG.

Tinker